Clinical trials: Glomerular Disease
Diabetes Mellitus, Type 2
How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine?
Pioglitazone is an insulin sensitising drug used in the treatment of patients with type 2 diabetes. In addition to its blood sugar lowering effect, pioglitazone also has a number of other beneficial effects, one of which is to…
- Trial name
- NCT00749047
- Testing
- Pioglitazone
- Where
- New Zealand
- Volunteers
- 12 people
- Sponsor
- Christchurch Hospital
Kidney Disease
Evaluation of New Test Method to Measure Kidney Function
This study will test the accuracy of a new "Fast GFR" (glomerular filtration rate) test to evaluate kidney function. Accurate assessment of kidney function is important in many clinical situations, including detecting kidney…
- Trial name
- NCT00026715
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C, Chronic Kidney Disease
Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)
Treatment protocol to see if people with hepatitis C (HCV) and chronic kidney disease (CKD) who are treated with Harvoni for 12 weeks have improvements in their kidney disease.
- Trial name
- NCT02503735
- Testing
- Sofosbuvir/Ledipasvir FDC
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Solid Tumour, Advanced Solid Malignancies
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
This is Phase I, open-label and dose escalation study to evaluate the safety and tolerability of AZD1480(JAK2 inhibitor) in Asian patients with advanced solid tumors (Part A and C) and in patients with advanced HCC (Part B) in…
- Conditions
- Solid Tumour, Advanced Solid Malignancies, Child-Pugh A to B7 Advanced Hepatocellular Carcinoma, EGFR and/or ROS Mutant NSCLC
- Trial name
- NCT01219543
- Testing
- AZD1480 Daily, AZD1480 BID
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Treatment
Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein Glomerulopathy
The purpose of this study is to assess the efficacy and safety of immunoadsorption in the treatment of lipoprotein glomerulopathy.
- Trial name
- NCT00302510
- Testing
- immunoadsorption
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
Renal Disease
Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy
Treatment with combination ACTHar gel and Tacrolimus therapy or ACTHar gel therapy alone in lowering urinary protein to creatinine (UP/Cr) ratios
- Trial name
- FACT (NCT04080076)
- Testing
- Acthar 80 UNT/ML Injectable Solution, Oral Tab Tacrolimus
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- NephroNet, Inc.
Anorexia Nervosa, Kidney Injury
Kidney Function and Anorexia Nervosa
Anorexia nervosa (AN) is an eating disorder that can lead to severe medical complications. Kidney injuries are unknown in patients with extremely malnourished AN (BMI <13).
- Trial name
- ANKID (NCT05327998)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Kidney Failure, Prostatic Hyperplasia
The Effect of Daily Tamsulosin 0.2mg Administration on Renal Function in Patients With Benign Prostatic Hyperplasia
The purpose of this study is to determine whether medical treatment for bladder outlet obstruction is effective in improvement of glomerular filtration rate and/or proteinuria.
- Trial name
- NCT02033798
- Testing
- Tamsulosin
- Where
- South Korea
- Volunteers
- 34 people
- Sponsor
- The Catholic University of Korea
Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental
Podocyte Retinoids
This is a pilot study of retinoids for patients with unsatisfactory response to conventional treatment of nephrotic syndrome due to focal segmental glomerulosclerosis or minimal change disease, two renal disorders associated with…
- Trial name
- NCT00098020
- Testing
- Isotretinoin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Disease, Albuminuria
Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria
Patients with chronic kidney disease (CKD) and albuminuria are at increased risk of developing cardiovascular disease (CVD) which is often associated with hypertension, left ventricular hypertrophy, endothelial dysfunction and…
- Trial name
- NCT00625820
- Testing
- 6R BH4, Vitamin C
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Michigan
Glomerulonephritis
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of KP104 in participants with IgAN and C3G. The study will start with enrolling the IgAN cohort.
- Trial name
- NCT05517980
- Testing
- KP104
- Volunteers
- 52 people
- Sponsor
- Kira Pharmacenticals (US), LLC.
Chronic Kidney Disease stage3
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of orally drugs for the treatment of type 2 diabetes. These drugs decrease plasma glucose levels by inhibiting its reabsorption in the proximal tubules of the…
- Trial name
- NCT04961931
- Testing
- Empagliflozin 10 MG
- Where
- Poland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Chronic Kidney Disease, Iron-deficiency Anemia
A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease
The long-term goal is to assess the fall in kidney function measured by glomerular filtration rate (GFR) when patients with chronic kidney disease (CKD) are exposed to intravenous iron (IVIR).
- Trial name
- NCT00830037
- Testing
- IV Iron, Ferrous Sulfate
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Indiana University
Diabetic Nephropathies, Kidney Failure, Chronic
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes.
- Conditions
- Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
- Trial name
- SUGARNSALT (NCT06217302)
- Testing
- Sotagliflozin
- Where
- 19 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Alessandro Doria
Acute Kidney Injury (Nontraumatic), Contrast-induced Nephropathy
Data on the Prevention of Complications of Prophylactic Intravenous Hydration in Patients With eGFR < 30
At Maastricht University Medical Centre (Maastricht UMC+) a specialised unit was established where a dual screening process including both renal and cardiac parameters is used to minimize the risk of contrast-induced acute kidney…
- Trial name
- CVP (NCT04592406)
- Testing
- CVP screening
- Where
- Netherlands
- Volunteers
- 443 people
- Sponsor
- Maastricht University Medical Center
Glomerular Filtration Rate, Acute Kidney Injury
Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers
The purpose of this early feasibility study was to investigate the pharmacokinetics of MP-3180 administered in rising doses and to evaluate the use of the Optical Renal Function Monitor (ORFM), an investigational noninvasive…
- Trial name
- ORFM-1B (NCT02098187)
- Testing
- Below target dose MP-3180, At target dose MP-3180, 2 times above target dose MP-3180
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- MediBeacon
Fabry Disease
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
This was a randomized, double-blind, active control study of the enzyme replacement therapy (ERT) drug PRX-102 (pegunigalsidase alfa) in Fabry disease patients with impaired renal function.
- Trial name
- BALANCE (NCT02795676)
- Testing
- PRX-102 (pegunigalsidase alfa), agalsidase beta
- Where
- 29 sites in United States, Czechia and 10 more
- Volunteers
- 78 people
- Sponsor
- Protalix
Berger Disease, Bergers Disease
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to <18 years with primary immunoglobulin A nephropathy (IgAN).
- Conditions
- Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
- Trial name
- ADVANCE (NCT07498335)
- Testing
- Drug: Atrasentan
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
C3 Glomerulopathy
Fabhalta Capsules Specified Drug-use Survey
The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.
- Trial name
- NCT07156149
- Where
- 29 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 1, Type1diabetes
Pilot Study DiaDEP
With an increased incidence of pediatric type 1 diabetes (T1D) and a decrease in age at diagnosis, children are exposed to complications such as renal impairment at a very young age.
- Trial name
- DiaDEP (NCT03912012)
- Testing
- Iohexol renal clearance measurement, microcirculation assessment through Laser Doppler associated to iontophoresis., Cardiovascular assessment though Intima-media Thickness and Extra-media Thickness measurement
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Hospices Civils de Lyon